ArticlesAnti-acid treatment and disease progression in idiopathic pulmonary fibrosis: an analysis of data from three randomised controlled trials
Introduction
Idiopathic pulmonary fibrosis (IPF) is a progressive, fibrotic lung disease of unknown cause. Median survival after diagnosis is 2–3 years.1, 2 Several treatments have been studied, but no treatment has been proven to affect clinically meaningful outcomes.3, 4, 5, 6, 7, 8 Evidence-based guidelines for the management of IPF published in 2011 recommended against routine use of all known pharmacological agents.2
Abnormal acid gastro-oesophageal reflux (diagnosed and differentiated from normal gastro-oesophageal reflux through 24-h pH monitoring) is common in patients with IPF9, 10, 11 and is deemed to be a risk factor for development of the disease.1 Data suggest that medical and surgical treatment of abnormal acid gastro-oesophageal reflux in patients with IPF might be beneficial, presumably because acidity and frequency of microaspiration are reduced.2, 12 Small case series have shown long-term stabilisation of forced vital capacity (FVC) and oxygenation in patients with IPF and documented abnormal acid gastro-oesophageal reflux who are treated with drugs or undergo surgery, or both.13, 14 Additional studies have established that pepsin is present in the bronchoalveolar lavage fluid of patients with acute exacerbation of IPF, suggesting that microaspiration of gastric contents as a result of gastro-oesophageal reflux has a role in this important clinical event.15 Most recently, a two-centre retrospective cohort study showed that self-reported use of anti-acid treatment at time of diagnosis (predominantly proton-pump inhibitors [PPIs]) was associated with significantly increased survival time.16 Thus, increasing evidence supports a role for abnormal acid gastro-oesophageal reflux and microaspiration in the pathogenesis and progression of IPF.12
The aim of this study was to establish the association between routine use of anti-acid treatment (PPIs or histamine-receptor-2 [H2] blockers, or both) and disease progression with use of prospective data from the placebo groups of three randomised clinical trials from the Idiopathic Pulmonary Fibrosis Clinical Research Network (IPFnet).3, 4, 5 Our hypothesis was that individuals who used anti-acid treatment would have slower disease progression and fewer clinically meaningful events than would those who did not use this treatment.
Section snippets
Study participants
In an analysis of data from three randomised controlled trials, we identified patients with IPF in the placebo groups of three studies: Sildenafil Trial of Exercise Performance in Idiopathic Pulmonary Fibrosis (STEP-IPF),3 Anticoagulant Effectiveness in Idiopathic Pulmonary Fibrosis (ACE-IPF),4 and Prednisone, Azathioprine, and N-Acetylcysteine: A Study That Evaluates Response in Idiopathic Pulmonary Fibrosis (PANTHER-IPF).5 Patients were enrolled into the trials between Sept 7, 2007, and Oct
Results
480 patients with IPF were enrolled into the three clinical trials (figure 1). Of the 242 patients randomly assigned to the placebo groups, 124 (51%) were taking either a PPI (n=113) or H2 blocker (n=11) at enrolment (figure 1). No patients were taking both a PPI and H2B. We recorded no significant differences in demographics, measures of disease severity, and self-reported outcome measures between patients taking and those not taking a PPI or H2 blocker (table 1). More patients taking a PPI or
Discussion
We have shown that FVC decreases more slowly in patients with well defined IPF who are taking a PPI or H2 blocker than in those who are not. A decrease in FVC has been correlated with reduced survival time in IPF,18, 19, 20, 21 and is used as a measure of disease progression.2 Therefore, our findings suggest that anti-acid treatment might be beneficial in patients with IPF and support the hypothesis that abnormal acid gastro-oesophageal reflux is important in IPF disease progression.22
The
References (39)
- et al.
Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials
Lancet
(2011) - et al.
Gastroesophageal reflux in patients with idiopathic pulmonary fibrosis referred for lung transplantation
J Thorac Cardiovasc Surg
(2007) - et al.
Sole treatment of acid gastroesophageal reflux in idiopathic pulmonary fibrosis: a case series
Chest
(2006) - et al.
Laparoscopic fundoplication in patients with end-stage lung disease awaiting transplantation
J Thorac Cardiovasc Surg
(2006) - et al.
Analyses of efficacy end points in a controlled trial of interferon-gamma1b for idiopathic pulmonary fibrosis
Chest
(2005) - et al.
Does chronic microaspiration cause idiopathic pulmonary fibrosis?
Am J Med
(2010) - et al.
Outcome of patients with idiopathic pulmonary fibrosis admitted to the ICU for respiratory failure
Chest
(2001) - et al.
Obstructive sleep apnea is common in idiopathic pulmonary fibrosis
Chest
(2009) - et al.
Nasal CPAP reduces gastroesophageal reflux in obstructive sleep apnea syndrome
Chest
(1992) Idiopathic pulmonary fibrosis: new evidence and an improved standard of care in 2012
Lancet
(2012)
Prognostic significance of histopathologic subsets in idiopathic pulmonary fibrosis
Am J Respir Crit Care Med
An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management
Am J Respir Crit Care Med
A controlled trial of sildenafil in advanced idiopathic pulmonary fibrosis
N Engl J Med
A placebo-controlled randomized trial of warfarin in idiopathic pulmonary fibrosis
Am J Respir Crit Care Med
Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis
N Engl J Med
Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis
N Engl J Med
BUILD-3: a randomized, controlled trial of bosentan in idiopathic pulmonary fibrosis
Am J Respir Crit Care Med
Increased prevalence of gastroesophageal reflux in patients with idiopathic pulmonary fibrosis
Am J Respir Crit Care Med
High prevalence of abnormal acid gastro-oesophageal reflux in idiopathic pulmonary fibrosis
Eur Respir J
Cited by (338)
Idiopathic pulmonary fibrosis
2023, Presse MedicaleIdiopathic pulmonary fibrosis: Diagnosis, biomarkers and newer treatment protocols
2023, Disease-a-MonthFrench practical guidelines for the diagnosis and management of idiopathic pulmonary fibrosis – 2021 update. Full-length version
2023, Respiratory Medicine and ResearchCurrent Imaging of Idiopathic Pulmonary Fibrosis
2022, Radiologic Clinics of North America